Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Junjie Zhang
CONTACT
Qianqian Zhang
CONTACT
Lead
Evopoint Biosciences Inc.
This is a multicenter, phase Ib/II clinical trial, divided into three parts: The part1 is the dose escalation study of XNW5004 combined with Enzalutamide (Dose escalation in phase Ib) . The part2 is the dose expansion study of XNW5004 combined with Enzalutamide (Dose expansion in phase IIa). The phase Ib and IIa will evaluate the safety, tolerability and preliminary anti-tumor activity of XNW5004 in combination with enzalutamide to determine the recommended phase II dose (RP2D). The part3 is an open label, randomized phase 2 study (Phase IIb). The patients with mCRPC will be enrolled to assess the efficacy of XNW5004 at the RP2D in combination with Enzalutamide in comparison with Enzalutamide alone.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted